Choueiri, T., Fishman, M. N., Escudier, B., Kim, J. J., Kluger, H., Stadler, W. M., … Sznol, M. (2014). 1051PDIMMUNOMODULATORY ACTIVITY OF NIVOLUMAB IN PREVIOUSLY TREATED AND UNTREATED METASTATIC RENAL CELL CARCINOMA (MRCC): BIOMARKER-BASED RESULTS FROM A RANDOMIZED CLINICAL TRIAL. Ann Oncol, 25(suppl_4), iv362. https://doi.org/10.1093/annonc/mdu342.4

Choueiri, T., M. N. Fishman, B. Escudier, J. J. Kim, H. Kluger, W. M. Stadler, J. L. Perez-Garcia, et al. “1051PDIMMUNOMODULATORY ACTIVITY OF NIVOLUMAB IN PREVIOUSLY TREATED AND UNTREATED METASTATIC RENAL CELL CARCINOMA (MRCC): BIOMARKER-BASED RESULTS FROM A RANDOMIZED CLINICAL TRIAL.” Ann Oncol 25, no. suppl_4 (September 1, 2014): iv362. https://doi.org/10.1093/annonc/mdu342.4.

Choueiri T, Fishman MN, Escudier B, Kim JJ, Kluger H, Stadler WM, et al. 1051PDIMMUNOMODULATORY ACTIVITY OF NIVOLUMAB IN PREVIOUSLY TREATED AND UNTREATED METASTATIC RENAL CELL CARCINOMA (MRCC): BIOMARKER-BASED RESULTS FROM A RANDOMIZED CLINICAL TRIAL. Ann Oncol. 2014 Sep 1;25(suppl_4):iv362.

Choueiri, T., et al. “1051PDIMMUNOMODULATORY ACTIVITY OF NIVOLUMAB IN PREVIOUSLY TREATED AND UNTREATED METASTATIC RENAL CELL CARCINOMA (MRCC): BIOMARKER-BASED RESULTS FROM A RANDOMIZED CLINICAL TRIAL.” Ann Oncol, vol. 25, no. suppl_4, Sept. 2014, p. iv362. Pubmed, doi:10.1093/annonc/mdu342.4.

Choueiri T, Fishman MN, Escudier B, Kim JJ, Kluger H, Stadler WM, Perez-Garcia JL, McNeel D, Curti B, Harrison MR, Plimack ER, Appleman L, Fong L, Drake CG, Cohen L, Srivastava S, Jure-Kunkel M, Hong Q, Kurland J, Sznol M. 1051PDIMMUNOMODULATORY ACTIVITY OF NIVOLUMAB IN PREVIOUSLY TREATED AND UNTREATED METASTATIC RENAL CELL CARCINOMA (MRCC): BIOMARKER-BASED RESULTS FROM A RANDOMIZED CLINICAL TRIAL. Ann Oncol. 2014 Sep 1;25(suppl_4):iv362.